The human receptor tyrosine kinases MET and RON (MST1R) (and their respective orthologs in other species) form a unique, two-member gene family that encodes proteins with identical modular structure that may perform similar functions. Oncogenic activating mutations of MET were discovered in hereditary renal carcinoma of the papillary type (1, 2) and a variety of common cancers (3). Oncogenic amplification and overexpression of MET were also reported previously (3). The involvement of RON in carcinogenesis is much less understood.
RON is a receptor tyrosine kinase of the MET family that is involved in cell proliferation
The human receptor tyrosine kinases MET and RON (MST1R) (and their respective orthologs in other species) form a unique, two-member gene family that encodes proteins with identical modular structure that may perform similar functions. Oncogenic activating mutations of MET were discovered in hereditary renal carcinoma of the papillary type (1, 2) and a variety of common cancers (3) . Oncogenic amplification and overexpression of MET were also reported previously (3) . The involvement of RON in carcinogenesis is much less understood.
We have recently discovered that RON is negatively controlled by the tumor suppressor protein HYAL2 and becomes activated in a ligand-independent mechanism upon HYAL2 removal, leading to cell transformation (4) . An oncogenic function of RON was also demonstrated in a transgenic model (5) .
RON is almost ubiquitously expressed (6 -8) in a variety of normal cell types (6, 9 -14) and also in a number of tumor cell lines (15) in which RON kinase activity is deregulated. The extracellular part of RON is comprised of a sema domain, a PSI 1 domain (plexin semaphorins integrins (16) , also known as MRS domain (MET-related sequence) (17) ), and four IPT domains (immunoglobulin-like fold shared by plexins and transcription factors (16) ). The functional role of these domains remains unknown. The sema domain (whose presence in RON and MET makes them a unique family among the approximate 20 receptor tyrosine kinase families identified by the Human Genome Project) is represented by a block of ϳ500 amino acids with 15 conserved cysteine residues intermingled with stretches of conserved amino acids and a conserved potential glycosylation site (18) . This domain is also present in semaphorins and plexins (a class of semaphorin receptors).
Secreted semaphorins and their receptors were initially discovered by their ability to induce axon steering and collapse of the growth cone in vitro, but it is now evident their biological function is not confined to the neural system and involves at least the immune (19, 20) , cardiovascular, and skeletal systems (21) in vertebrates. Semaphorins are also overexpressed in metastasizing cancer cells (22, 23) , possibly facilitating cell dissociation and survival. Because the sema domain of semaphorins mediates receptor specificity (24), we reasoned that the sema domain of RON might contain the ligand-binding region.
In this study, we show that two soluble molecules designed over the sema and sema ϩ PSI domains of RON (referred to as "ron-sema" and "ron-PSI," respectively) undergo correct posttranslational processing and are secreted when expressed in mammalian cells. Both molecules inhibit ligand binding to the RON receptor (both ␣-and ␤-MSP-binding sites), indicating that the RON sema domain may contain the ligand-binding sites and mediate ligand-binding specificity. In addition, we found that these secreted soluble molecules have a highly specific dominant-negative effect on RON kinase activation. Such activity extends to inhibiting the proliferation of MSP-sensitive cells in culture, including cancer cell lines. This highlights the potential therapeutic use of the secreted soluble molecules ron-sema and ron-PSI to inhibit MSP-dependent tumor growth.
The forced expression of these secreted soluble molecules could represent a gene therapy tool to treat MSP-dependent types of cancer.
EXPERIMENTAL PROCEDURES
Materials-Human recombinant ␣-␤-heterodimeric MSP, free MSP ␣-and ␤-chains, and recombinant mouse MSP receptor RON/Fc chimera were from R&D Systems (Minneapolis, MN). Human EGF was from Invitrogen. Human recombinant HGF was a gift from Dr. P. Godowski (Genentech, San Francisco, CA). Rabbit and mouse anti-MSP antibodies were described previously (25) . Rabbit anti-human RON (C-20), goat anti-human EGFR (1005-G), rabbit anti-human MET (C-28), and goat anti-mouse MET (SP260) were from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal anti-phosphotyrosine (Clone 4G10) and anti-FLAGM2 antibodies were from Upstate Biotechnology (Lake Placid, NY). Monoclonal anti-phospho-MAPK antibody (E10) was from Cell Signaling Technology (Beverly, MA). Monoclonal anti-MAPK (ERK1/2) antibody was from Transduction Laboratories (Lexington, KY). Other chemicals were from Sigma or Invitrogen.
Constructs and Cloning Procedures-ron-sema was amplified by PCR from RON cDNA with the primers 17 forward (5Ј-CAG CTC GCC TCG ATG GAG-3Ј) and 1583 reverse (5Ј-GGA AAA CCT GGT CCC CAG AGG-3Ј) in 1.5 mM MgCl 2 under the following PCR conditions: 5 min at 95°C; 35 times (1 min at 95°C, 30 s at 64°C, and 2 min at 72°C); and 7 min at 72°C. The PCR product (1549 bp, 519 amino acids) was cloned into pCR2.1 (Invitrogen), sequenced, and cloned into the HindIII/EcoRV restriction sites of the pFLAG-CMV-2 expression vector (Sigma).
ron-PSI was PCR amplified with the primers (ABI Applied Biosystems, Frederick, MD) 17 forward (5Ј-CAG CTC GCC TCG ATG GAG-3Ј) and 1762 reverse (5Ј-ACT GTG GGG GTG GAA CTC AGT AAG C-3Ј) in 1.5 mM MgCl 2 under the same cycling conditions. The 1747-bp PCR product (578 amino acid) was first cloned into pCR2.1 (Invitrogen), sequenced, and cloned into the HindIII sites of pFLAG-CMV-2 (Sigma). The primer location is given according to GenBank TM accession number X70040. Sequencing was performed with ABI 373 stretch automated DNA sequencer (Applied Biosystems). Human MET cDNA was kindly provided by Dr. L. Schmidt (Laboratory of Immunobiology, SAIC-NCI, Frederick, MD).
Cell Lines-HEK 293, HEK293T, MDCK, and colon cancer HCT116 cell lines were from ATCC (Manassas, VA). RE7 cell line (MDCK cells stably expressing human RON) was described previously (26) . Cells were cultured in media containing 10% fetal calf serum according to ATCC recommendation.
Transfections-HEK293 and HEK293T cells were grown in Dulbecco's modified Eagle's medium with 10% fetal calf serum. For transient transfection, cells were grown to 80 -90% confluence on 10-cm dishes and transfected with 30 g of cDNAs of the empty vector or the ronsema or ron-PSI construct using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. 6 h after transfection, the medium was replaced by 6 ml/dish serum-free Dulbecco's modified Eagle's medium and cells were incubated for 3 days. The 3-day-old conditioned media were collected and analyzed for the presence of ron-sema or ron-PSI proteins by immunoprecipitation and Western blotting. HEK 293 cells were similarly transiently transfected with human MET cDNA.
Cell Stimulation, Immunoprecipitation, and Western blotting-Cells were starved overnight in serum-free medium and then stimulated for 15 min with 5 nM MSP or 50 ng/ml EGF or 100 ng/ml HGF diluted in preconditioned culture medium containing secreted ron-sema or ron-PSI. Preconditioned medium of non-transfected cells was used as negative control. After stimulation, cells were lysed in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 100 mM NaF, 1% Triton X-100, 10 g/ml leupeptin, 10 units/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride). Insoluble material was removed by low-speed centrifugation. Supernatants were further analyzed. Molecules of interest were immunoprecipitated from cleared lysates by appropriate antibodies added with protein G-agarose to the lysates. After overnight incubation at 4°C, immunoprecipitates were washed three times with HNTG buffer (50 mM HEPES, 150 mM NaCl, 0.1% Triton X-100, 10% glycerol). 15 l of 2ϫ SDS-PAGE sample buffer were added to each tube. After 5 min of boiling, precipitated proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. Membrane-bound protein bands were visualized with appropriate antibodies according to standard Western blotting procedures. Cleared total cell lysates were used in SDS-PAGE and Western blotting for detection of MAPK activation.
In Vitro Cell Proliferation Assay-RE7 cells (MDCK cells stably expressing the human RON receptor) (26) were plated (2 ϫ 10 3 cells/ well) in triplicate in 96-well plates and incubated with 5 nM MSP diluted in serum-free Dulbecco's modified Eagle's medium plus preconditioned culture medium containing secreted ron-sema or ron-PSI (final ratio 1:1). Conditioned medium of non-transfected cells was used as negative control. HCT116 colon cancer cells (2 ϫ 10 3 cells/well) were distributed in duplicates in 24-well plates and incubated with or without 5 nM MSP in McCoy serum-free medium plus preconditioned culture medium containing ron-sema or ron-PSI (final ratio 1:1). Cell number was determined after 72 h by adding 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into culture wells and measuring A 570 2 h later. Cell number was determined from an MTT calibration curve specific for each cell line.
ELISA-All of the experiments were performed as described previously (27) . ELISA microtiter plates were coated overnight at 4°C with recombinant mouse MSP-receptor RON/Fc (mrRON/Fc) chimera (R&D Systems, Inc.) (100 l/well at 0.5 g/ml in carbonate-bicarbonate buffer, pH 9.6). Unspecific binding sites were blocked with 1% bovine serum albumin (1 h at 37°C). Subsequently, RON-coated ELISA plates were incubated for 2 h with a series of 2-fold dilutions of human recombinant MSP (highest concentration, 2 nM), free ␤-chain (highest concentration, 2 nM), or free ␣-chain (highest concentration, 100 nM) in culture medium from HEK293T cells transiently transfected with empty vector (negative control) or ron-sema cDNA construct. ELISA plates were then washed three times with Tris-buffered saline-Tween 20. Plates were then incubated for 2 h with rabbit polyclonal anti-MSP antibodies. Bound rabbit anti-MSP was detected by equilibration with alkaline phosphatase-conjugated anti-rabbit IgG. Substrate 104 (Sigma) was used for quantifying alkaline phosphatase activity. A 405 was measured with an ELISA reader. At least three independent experiments were performed. The effect caused by ron-sema on MSP binding, ␤-chain binding, and ␣-chain binding to mrRON/Fc was calculated in percent inhibition versus the effects of the control culture medium at each experimental point. The binding of MSP ␣-or ␤-chains in the presence of the blank medium (preconditioned medium of non-transfected cells) was counted as 100%.
RESULTS

The Expression Constructs Designed over the sema and sema ϩ PSI Domains of RON Are Correctly Processed and Secreted
after Translation-The sema domain is characterized by the presence of ϳ15 highly conserved cysteine residues interspersed in ϳ500 amino acids (18) . The PSI domain contains eight conserved cysteines distributed in ϳ50 residues. Initially, it was part of the definition of sema domain but because not all of the semaphorines contain a PSI domain, this modular structure was redefined (16) . The minimal consensus sequence for the PSI domain was described previously (16, 17) 
To obtain a soluble molecule that could mimic the activity of ron-sema and sema ϩ PSI domains, we amplified by PCR these regions from RON cDNA and cloned them into expression vectors. On the basis of a consensus sequence for the sema domain (16), we designed PCR primers to amplify a cDNA stretch corresponding to the N-terminal part of the protein up to amino acid Phe-518 (this molecule is referred to as ron-sema in Fig. 1B) . A region comprising up to amino acid Ser-578 was amplified for the longer sema ϩ PSI domain (referred to as ron-PSI). All of the residues in the N-terminal sequence were amplified, starting from the first ATG to include the first 24 amino acids of the predicted signal peptide (9) . An expression vector was chosen that provides an N-terminal FLAG but no artificial signal peptide. Western blot in reducing conditions of proteins immunoprecipitated with anti-FLAG antibodies from the conditioned culture medium of HEK293T cells transfected with each construct, respectively, shows two bands of approximately 70 and 35 kDa. The upper bands (Fig. 1B, left panel) correspond to the uncleaved soluble molecules ron-sema and ron-PSI. The lower band (Fig. 1B, left panel) corresponds to the ␣-chain alone (derived from the predicted cleavage at the KRRR site), identifiable through the fusion with the FLAG epitope. The frag-ment of ␤-chain is released after the reduction of the disulfide bonds, which in the mature receptor connect the two chains together, and remains undetectable by anti-FLAG antibodies used in this experiment. The upper band migrates with a molecular weight higher than expected, most probably because of post-translational events such as N-glycosylation and Nmyristoylation predicted by sequence analysis (28) . In nonreducing conditions (Fig. 1B, right panel) , the soluble molecules, consisting of ␣-and ␤-chain fragment held together by the disulfide bonds, migrate with a molecular mass slightly higher than 70 kDa. These results show that the constructs are formation of ligand-receptor complexes. As shown in Fig. 2A , MSP can be co-immunoprecipitated with RON. The presence of ron-sema in the culture medium during cell stimulation with MSP reduces the amount of MSP co-immunoprecipitated with RON ( Fig. 2A, lane 4) .
MSP is a heterodimer comprised of ␣-and ␤-chains linked by a disulfide bond. Two binding sites for RON have been identified in MSP. MSP ␤-chain contains the high affinity binding site (29) , whereas the ␣-chain contains a second low affinity receptor-binding site (30) . Neither ␣-nor ␤-chain of MSP alone induces RON tyrosine phosphorylation and activation, indicating that both binding sites of MSP are required for biological activity (29) .
We used a competitive ELISA to investigate the effect of soluble ron-sema on the binding of recombinant disulfidelinked ␣-␤-heterodimeric MSP and free ␣-and ␤-chains of MSP to recombinant RON receptor adsorbed to an ELISA plate (Fig.  2B) . The binding of recombinant disulfide-linked ␣-␤-MSP, free ␣-chain, and free ␤-chain to recombinant ron receptor is inhibited by the presence of ron-sema in the reaction mixture (Fig. 2B) .
The Soluble Molecules ron-sema and ron-PSI Inhibit MSPinduced Signaling and Cell Growth-Our finding that ronsema (Fig. 2B ) and ron-PSI (data not shown) inhibits MSPbinding to RON suggested that these soluble molecules might inhibit MSP-induced RON activation via competition for MSP binding. To investigate whether the soluble molecules ronsema and ron-PSI may functionally interfere with the activity of the full-length receptor, we stimulated RON-expressing RE7 cells (26) with MSP in a culture medium containing either molecule (or none as a control). The RON receptor was then immunoprecipitated from these cell lysates with anti-RON antibodies and a Western blot performed with anti-phosphotyrosine antibodies. The result shows a greatly reduced level of phosphorylation of the receptor immunoprecipitated from cells exposed to a conditioned culture medium containing ron-sema or ron-PSI molecules compared with the control (Fig. 3A) .
Ligand-induced RON-tyrosine phosphorylation is a key event leading to up-regulation of RON catalytic activity and consequent activation of intracellular signaling pathways that mediate the biological effects of MSP (31) . A decrease in RON tyrosine phosphorylation by soluble ron-sema or ron-PSI molecules resulted in the inhibition of RON-dependent signaling pathways.
In RE7 cells exposed to non-conditioned medium, MSP induces a strong phosphorylation of MAPK (Fig. 3B) , a kinase known to be part of signaling pathways that control MSP-dependent cell proliferation (reviewed in Refs. [32] [33] [34] . When RE7 cells are exposed to ron-sema or ron-PSI, the level of MSPinduced MAPK phosphorylation is strongly reduced (Fig. 3B) . This inhibiting effect on MAPK phosphorylation translates directly into cell proliferation inhibition. A growth rate experiment was performed on RON-transfected cells stimulated with MSP. Under the experimental conditions described, MSP has a strong mitogenic effect that is greatly reduced in the presence of soluble ron-sema and ron-PSI with ron-PSI causing a 3-fold reduction of growth compared with the control (Fig. 3C) . These results show that the secreted soluble molecules designed over the sema and sema ϩ PSI domains of RON are capable of inhibiting RON phosphorylation and therefore activation induced by MSP.
MSP-induced RON activation in tumor cells including breast carcinoma-derived ZR75.1 cell line, colon cancer cell line HCT116, and lung carcinomas correlates with cell proliferation, migration, and invasion (14, 35-37) . Thus, ligand-induced RON stimulation can be associated with tumor progression. We investigated the effect of soluble ron-sema and ron-PSI on MSP-dependent RON activation and cell proliferation of the colon cancer cell line HCT116.
In this cell line, MSP induces RON-tyrosine phosphorylation (Fig. 4A) and promotes cell growth (Fig. 4B) . The presence of 3 /well) were distributed in triplicate in 96-well plate and incubated with or without 5 nM MSP in serum-free Dulbecco's modified Eagle's medium in the presence of blank medium or conditioned medium containing either ron-sema or ron-PSI-soluble molecules. Cell number was measured after 72 h of cell culturing by adding MTT to culture wells and measuring A 570 2 h later. The number of cells was determined with a standard calibration curve. Error bars, means ϩ S.E. for three independent experiments. The inhibitory effect of ron-sema on RON and MAPK phosphorylation (Fig. 3, A and B) seems stronger that its effect on cell proliferation (Fig. 3C) and vice versa for ron-PSI. This difference could be because of the different duration of the biochemical (15 min) and proliferation studies (3 days). In these conditions, it is likely that the relative stability of soluble ron-sema and ron-PSI are different and certainly affected by the cell type-specific proteases secreted in the culture medium (compare Figs. 3C and 4B ). either ron-sema or ron-PSI inhibits MSP-mediated RON activation (Fig. 4A ) and cell growth (Fig. 4B) . These results suggest that the dominant-negative molecules ron-sema and ron-PSI may have a therapeutic application. They may prevent MSP/ RON-mediated cancer cell growth.
ron-sema Effect Is Highly Specific for the RON Receptor-RON and MET have overall 33% identity and share the same modular organization, including the presence of sema and PSI domains in their extracellular part. To rule out the possibility that ron-sema might interfere non-specifically with MET (which shares the highest homology with RON) or other growth factor receptors, we incubated MET-ligand HGF in preconditioned culture medium with or without ron-sema (or ron-PSI, data not shown).
In this experiment, MET was immunoprecipitated with anti-MET antibodies from cell lysates of MDCK (cells naturally expressing MET) previously treated with HGF. Western blotting performed with anti-phosphotyrosines antibodies (Fig. 5A) shows that HGF increases MET tyrosine phosphorylation and ron-sema does not affect MET phosphorylation. Similar results were obtained with HEK 293 cells transiently transfected with human MET cDNA (data not shown). As a further control, the effect of ron-sema on EGF-induced EGFR phosphorylation was investigated. Cells expressing EGFR were stimulated with EGF in the presence or absence of ron-sema. As shown (Fig.  5B) , the presence of ron-sema has no effect on the receptor phosphorylation triggered by EGF. 3 /well) were distributed in duplicates in 24-well plates and incubated with or without 5 nM MSP in serum-free McCoy medium in the presence of blank medium or conditioned media containing either ron-sema or ron-PSI. Cell number was measured after 72 h of culturing by adding MTT to culture wells and measuring A 570 after 2 h. The cell number was determined from a standard calibration curve. Error bars, means ϩ S.E. for two independent experiments. In the naturally RONexpressing HCT116 cells, the inhibitory effect on RON phosphorylation of ron-sema seems weaker than the ron-PSI effect. This is the opposite of what is shown in the transfected cells RE7. This difference shows that possibly RON activation could be inhibited not only via blocking MSP binding but also by interfering with its binding to other molecules (such as integrins, HYAL2, and so forth). Also, a cell-type specific pattern of post-translational modification of RON may affect a relative sensitivity to the presence of ron-sema and ron-PSI. These results show that the soluble molecule ron-sema does not affect ligand-stimulated phosphorylation of other growth factor receptors such as EGFR and, more importantly, MET, which has a highly homologous sema domain in the extracellular region.
DISCUSSION
This paper reports experimental evidence that secreted soluble proteins representing the sema or sema ϩ PSI domains of the tyrosine kinase receptor RON have highly specific dominant-negative effects on ligand-induced RON activation and downstream signaling events.
The sema domain is represented by a block of ϳ500 amino acids with 15 conserved cysteine residues spaced by stretches of conserved amino acids and a conserved potential glycosylation site (18) . A similar domain is also present in semaphorins and plexins (a class of semaphorin receptors).
At least in plexins, it was shown previously (38) that the cysteine-rich domain present in the extracellular region of the receptor mediates cell adhesion via plexin-plexin interaction, i.e. through homophilic binding. It would be interesting to investigate whether the PSI domain present on integrin ␤-chain exerts a direct interaction with the sema or PSI domains of RON in the context of the MSP-mediated integrin-dependent mechanism of cell adhesion and motility in which RON is involved (39) .
The observation ( Fig. 2A) that the presence of soluble ronsema proteins in the medium inhibits RON activation suggests that the ron-sema molecule interferes with MSP binding, either by sequestering MSP or by competitive binding to the sema domain of the receptor itself. Further experiments are needed to clarify this point.
The observation that RON can be expressed on the cell surface as a non-covalently linked dimer (40) raises the possibility that RON-RON association might be mediated by homophilic interactions between sema or PSI domains or both of two RON molecules. However, using cross-linking reagents, we were unable to detect a complex between full-length transmembrane RON and ron-sema or ron-PSI molecules (data not shown). These results argue that other parts of the receptor might be necessary for homophilic dimerization.
Possibly, the sema and/or PSI domain could also mediate interaction with other sema domain-containing proteins. Recently, a complex between Plexin B1 (a semaphorin receptor) and the MET receptor, co-expressed on the surface of the same cell, has been detected (41) . The binding of SEMA4D to Plexin B1 up-regulates MET kinase activity and induces tyrosine phosphorylation of both MET and Plexin B1 receptors. The receptor activation results in triggering cell dissociation and invasive growth. Cells lacking MET expression did not respond to SEMA4D (41) . Plexin B1 and MET association is specific, non-covalent, and requires the extracellular domains of both receptors (41) . These data suggest that the sema domain of MET might be responsible for association with Plexin B1. At the present time, there are no sema-containing proteins identified as RON partners. However, the observations that (i) RON knock-out is lethal but MSP (RON ligand) knock-out is not (42, 43) and (ii) Met-interacting semaphorins have been identified (41) suggest that in addition to MSP, RON might interact with other ligands or may have other sema-containing partners during normal development.
We hypothesized and investigated the possibility that RON sema-domain determines the ligand-binding specificity of the full-length receptor. MSP is a protein that belongs to the plasminogen-related kringle protein family (44) . It is most closely related to hepatocyte growth factor. Biologically active MSP is a disulfide-linked ␣-␤-heterodimer (31) that carries two binding sites for RON, a low affinity site and a high affinity site located on the ␣-and the ␤-chains, respectively (27, 29) . Although free ␣-and ␤-chains can bind to RON, only mature heterodimeric MSP induces RON kinase activation and cellular responses (29) . According to the proposed model, a single molecule of MSP induces RON dimerization (30) . In this work, we found that possibly both low and high affinity MSP binding sites are localized in the RON sema domain (Fig. 2) . This finding, together with the proposed MSP/RON interaction model (31) , suggests that soluble ron-sema may inhibit MSP/ RON-mediated cellular responses via competition for MSP binding.
We found that indeed incubation of RON-expressing cells with soluble ron-sema or ron-PSI causes a decrease of MSPinduced RON phosphorylation (Figs. 3A and 4A ) and RON-dependent MAPK activation (Fig. 3B ) along with the inhibition of MSP-mediated cell growth (Fig. 4B) . The activity of soluble ron-sema and ron-PSI is specific, because there is no effect on MET or EGF receptor ligand-induced tyrosine phosphorylation (Fig. 5) . Thus, the soluble molecule corresponding to the sema domain of RON, expressed separately from the receptor protein scaffold, can act as a specific dominant-negative regulator of RON activity.
Truncated dominant-negative receptor forms on the cell surface, tissue culture supernatants, and biological fluids have been detected for a number of growth factor receptors including Met (45, 46) . C-terminally truncated receptors (lacking the kinase domain) can interfere with ligand-induced stimulation via the formation of inactive heterodimers when they are expressed together with the full-length receptors or by competing for ligand binding when they are present in soluble forms. Two C-terminal truncated forms of MET were identified (45) . They carry an intact ligand-binding domain but lack the kinase domain because of truncation of the ␤-chain and arise from alternative post-transcriptional processing of the mature form. One truncated form is soluble and released from the cells (45) . These isoforms may have a physiological role in down-regulating MET functional activity. Truncated naturally occurring forms of RON lacking the kinase domain have not yet been identified.
The ability of ron-sema and ron-PSI to inhibit ligand-dependent RON activation and subsequent MSP/RON-mediated biological responses in vitro suggests a potential therapeutic use of such soluble molecules. RON expression has been detected in a number of cancer cell lines and tumors (reviewed in Ref. 15 ), whereas it is barely detectable in the corresponding normal cells. Autocrine and paracrine MSP-dependent mechanisms of RON activation could contribute to tumor growth and metastasis. Simultaneous RON and MSP expression has been found in a subset of non-small lung carcinomas (14) . MSP supports cell growth and migration of breast and colon cancer cell lines (35, 36) . Thus, interfering with MSP/RON autocrine/paracrine loops might be an approach for therapy of MSP-sensitive tumors. In the present work, we investigated the effect of the soluble molecule ron-sema on growth of the colon cancer cell line HCT116. It was shown that MSP stimulation induces RON tyrosine-phosphorylation and invasive growth of HCT116 cells (36) . Our results are in agreement with previously published data (36) . Moreover, the incubation in conditioned media containing soluble molecules ron-sema or ron-PSI inhibited MSPdependent RON tyrosine phosphorylation (Fig. 4A ) and cell growth (Fig. 4B) of HCT116 cancer cells.
In conclusion, we demonstrated that the sema domain of RON (which presumably contains the MSP binding sites) might serve as a dominant negative form of the RON receptor via competition for MSP binding to the full-length trans-mem-brane RON, thus possibly preventing RON-RON active dimer formation. These data suggest a potential therapeutic use of the soluble RON sema domain for preventing proliferation and migration of MSP-sensitive cancer cells and therefore inhibiting growth of MSP-sensitive types of cancer.
